Lecanemab API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Lecanemab API 1260393-98-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Lecanemab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Lecanemab
- Synonyms:
- Immunoglobulin G1, anti-(human beta-amyloid protofibril) (human-mus musculus monoclonal BAN2401 heavy chain), disulfide with human-mus musculus monoclonal BAN2401 light chain, dimer , Lecanemab
- Cas Number:
- 1260393-98-3
- DrugBank number:
- DB14580
- Unique Ingredient Identifier:
- 12PYH0FTU9
General Description:
Lecanemab, identified by CAS number 1260393-98-3, is a notable compound with significant therapeutic applications. Lecanemab is a humanized IgG1 monoclonal version of mAb158, a murine monoclonal antibody that reduces the levels of pathogenic amyloid beta (Aβ) and prevent Aβ deposition. Due to its amyloid plaque-lowering activity and its high selectively to Aβ protofibrils (1000-fold higher selectivity compared to monomers), lecanemab is currently investigated as a disease-modifying biologic for the treatment of Alzheimer's disease. A phase 2 clinical study showed that lecanemab did not meet the 12-month primary endpoint of reaching an 80% probability of ≥25% clinical reduction in Alzheimer's disease decline versus placebo. However, 18-month analyses demonstrated a reduction in brain amyloid accompanied by a consistent reduction of clinical decline across several clinical and biomarker endpoints. A phase 3 clinical study in early Alzheimer's disease is currently being developed.
Mechanism of Action:
Lecanemab functions by: Lecanemab is a humanized IgG1 monoclonal antibody currently investigated for the treatment of Alzheimer's disease, a condition characterized by the presence of plaque deposits of the amyloid beta (Aβ) peptide and neurofibrillary tangles. However, Aβ peptides exist in various conformational states, including soluble monomers, soluble aggregates of increasing size, and insoluble fibrils and plaque. Soluble Aβ aggregates such as Aβ protofibrils are more toxic than monomers or insoluble fibrils. Therefore, it has been hypothesized that by targeting and reducing the amount of Aβ protofibrils, lecanemab may be used to treat Alzheimer's disease. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Lecanemab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Categories:
Lecanemab is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Blood Proteins, Globulins, Immunoglobulins, Immunoproteins, Proteins, Serum Globulins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Lecanemab is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
